• Innovent reported that the Phase 3 STAR registration study (NCT05972473) of efdamrofusp alfa (IBI302) in Chinese patients with neovascular age-related macular degeneration met its primary endpoint at Week 52.
• Mean best corrected visual acuity change from baseline at Week 52 was 10.37 ETDRS letters for IBI302 8 mg versus 10.11 letters for aflibercept 2 mg.
• During the maintenance period, 86.2% of participants in the IBI302 group reached dosing intervals of at least every 12 weeks, including 72.8% at every 16 weeks.
• Macular atrophy incidence at Week 52 was 1.5% with IBI302 and 2.9% with aflibercept.
• Innovent said follow-up is ongoing through 100 weeks and the complete dataset is expected to be presented at future academic conferences or published in peer-reviewed journals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603232000PR_NEWS_USPR_____CN16509) on March 24, 2026, and is solely responsible for the information contained therein.